93 related articles for article (PubMed ID: 24928009)
1. [Effect of PARP1 inhibitor PJ34 on multi-drug resistance in human multiple myeloma cell line and its relationship with FA/BRCA pathway].
Xiong T; Wei H; Chen X; Xiao H
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2014 Jun; 31(3):312-6. PubMed ID: 24928009
[TBL] [Abstract][Full Text] [Related]
2. PJ34, a poly(ADP-ribose) polymerase (PARP) inhibitor, reverses melphalan-resistance and inhibits repair of DNA double-strand breaks by targeting the FA/BRCA pathway in multidrug resistant multiple myeloma cell line RPMI8226/R.
Xiong T; Wei H; Chen X; Xiao H
Int J Oncol; 2015 Jan; 46(1):223-32. PubMed ID: 25351371
[TBL] [Abstract][Full Text] [Related]
3. Reversal of multidrug resistance by curcumin through FA/BRCA pathway in multiple myeloma cell line MOLP-2/R.
Xiao H; Xiao Q; Zhang K; Zuo X; Shrestha UK
Ann Hematol; 2010 Apr; 89(4):399-404. PubMed ID: 19756599
[TBL] [Abstract][Full Text] [Related]
4. Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma.
Yarde DN; Oliveira V; Mathews L; Wang X; Villagra A; Boulware D; Shain KH; Hazlehurst LA; Alsina M; Chen DT; Beg AA; Dalton WS
Cancer Res; 2009 Dec; 69(24):9367-75. PubMed ID: 19934314
[TBL] [Abstract][Full Text] [Related]
5. [Reversal of multidrug resistance of the drug resistant human multiple myeloma cell line MOLP-2/R by curcumin and its relation with FA/BRCA pathway].
Xiao H; Zhang KJ; Zuo XL
Zhonghua Xue Ye Xue Za Zhi; 2009 Jan; 30(1):33-7. PubMed ID: 19563033
[TBL] [Abstract][Full Text] [Related]
6. Influence of PJ34 on the genotoxicity induced by melphalan in human multiple myeloma cells.
Xiong T; Chen X; Wei H; Xiao H
Arch Med Sci; 2015 Apr; 11(2):301-6. PubMed ID: 25995744
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of proliferation and invasiveness of ovarian cancer C13* cells by a poly(ADP-ribose) polymerase inhibitor and the role of nuclear factor-κB.
Wang Z; Li Y; Lv S; Tian Y
J Int Med Res; 2013 Oct; 41(5):1577-85. PubMed ID: 24097829
[TBL] [Abstract][Full Text] [Related]
8. The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells.
Chen Q; Van der Sluis PC; Boulware D; Hazlehurst LA; Dalton WS
Blood; 2005 Jul; 106(2):698-705. PubMed ID: 15802532
[TBL] [Abstract][Full Text] [Related]
9. BRCA/Fanconi anemia pathway implicates chemoresistance to gemcitabine in biliary tract cancer.
Nakashima S; Kobayashi S; Nagano H; Tomokuni A; Tomimaru Y; Asaoka T; Hama N; Wada H; Kawamoto K; Marubashi S; Eguchi H; Doki Y; Mori M
Cancer Sci; 2015 May; 106(5):584-91. PubMed ID: 25736055
[TBL] [Abstract][Full Text] [Related]
10. Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity.
Zhang HR; Chen JM; Zeng ZY; Que WZ
J Int Med Res; 2013 Jun; 41(3):584-95. PubMed ID: 23613505
[TBL] [Abstract][Full Text] [Related]
11. The Fanconi anemia/BRCA pathway is involved in DNA interstrand cross-link repair of adriamycin-resistant leukemia cells.
Yao C; Du W; Chen H; Xiao S; Huang L; Chen F
Leuk Lymphoma; 2015 Mar; 56(3):755-62. PubMed ID: 24996439
[TBL] [Abstract][Full Text] [Related]
12. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
Olaussen KA; Adam J; Vanhecke E; Vielh P; Pirker R; Friboulet L; Popper H; Robin A; Commo F; Thomale J; Kayitalire L; Filipits M; Le Chevalier T; André F; Brambilla E; Soria JC
Lung Cancer; 2013 May; 80(2):216-22. PubMed ID: 23410825
[TBL] [Abstract][Full Text] [Related]
13. Reduced PAK1 activity sensitizes FA/BRCA-proficient breast cancer cells to PARP inhibition.
Villamar Cruz O; Prudnikova TY; Araiza-Olivera D; Perez-Plasencia C; Johnson N; Bernhardy AJ; Slifker M; Renner C; Chernoff J; Arias-Romero LE
Oncotarget; 2016 Nov; 7(47):76590-76603. PubMed ID: 27740936
[TBL] [Abstract][Full Text] [Related]
14. Arsenic exposure disrupts the normal function of the FA/BRCA repair pathway.
Peremartí J; Ramos F; Marcos R; Hernández A
Toxicol Sci; 2014 Nov; 142(1):93-104. PubMed ID: 25092648
[TBL] [Abstract][Full Text] [Related]
15. PJ34, an inhibitor of PARP-1, suppresses cell growth and enhances the suppressive effects of cisplatin in liver cancer cells.
Huang SH; Xiong M; Chen XP; Xiao ZY; Zhao YF; Huang ZY
Oncol Rep; 2008 Sep; 20(3):567-72. PubMed ID: 18695907
[TBL] [Abstract][Full Text] [Related]
16. An inverse switch in DNA base excision and strand break repair contributes to melphalan resistance in multiple myeloma cells.
Sousa MM; Zub KA; Aas PA; Hanssen-Bauer A; Demirovic A; Sarno A; Tian E; Liabakk NB; Slupphaug G
PLoS One; 2013; 8(2):e55493. PubMed ID: 23405159
[TBL] [Abstract][Full Text] [Related]
17. Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma.
Turner JG; Cui Y; Bauer AA; Dawson JL; Gomez JA; Kim J; Cubitt CL; Nishihori T; Dalton WS; Sullivan DM
Cancer Res; 2020 Dec; 80(23):5344-5354. PubMed ID: 33023948
[TBL] [Abstract][Full Text] [Related]
18. [Antiproliferative effect of curcumin combined with cyclophosmide on the growth of human lymphoma cell line HT/CTX with drug resistance and its relation with FA/BRCA pathway].
Xiao H; Zhang KJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):804-8. PubMed ID: 18718065
[TBL] [Abstract][Full Text] [Related]
19. p63 involvement in poly(ADP-ribose) polymerase 1 signaling of topoisomerase I-dependent DNA damage in carcinoma cells.
Montariello D; Troiano A; Malanga M; Calabrò V; Quesada P
Biochem Pharmacol; 2013 Apr; 85(7):999-1006. PubMed ID: 23376119
[TBL] [Abstract][Full Text] [Related]
20. Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Sensitivity in Fanconi Anemia Head and Neck Cancers.
Lombardi AJ; Hoskins EE; Foglesong GD; Wikenheiser-Brokamp KA; Wiesmüller L; Hanenberg H; Andreassen PR; Jacobs AJ; Olson SB; Keeble WW; Hays LE; Wells SI
Clin Cancer Res; 2015 Apr; 21(8):1962-72. PubMed ID: 25609062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
